Month: May 2025

— Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 — — 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 — — Raises 2025 guidance; expects to generate $255 – $265 million in net product revenue and cash flow of $30 – $40 million, driven by 3,400 – 3,600 patients on LUMRYZ by year end — — Federal Circuit ruled in Avadel’s favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) —         — On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ...

– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer’s disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. “During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “For VG-3927, we reported positive Phase 1 data in January 2025...

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales SYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 millionIncrease in demand offset by inventory dynamics and funding shortages at co-pay assistance programsReceived U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGN On track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025 Cash and cash equivalents of $358.4 million as of March 31, 2025; projected revenues and cash expected to be sufficient to fund operations to profitability Management to host conference call today at 8:30...

In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres’ live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions in support of further development in allo-HSCT and potential expansion into other target populations Conference call at 8:30 a.m. ET today CAMBRIDGE,...

Revenue:$304.1 million for Q1 2025Net Income:$41.7 million for Q1 2025Earnings per common unit:$1.38 for Q1 2025Net cash from operating activities:$156.6 million for Q1 2025EBITDA:$147.6 million for Q1 2025Returning capital to unitholders:423,984 common units repurchased in 2025 (through May 1st) for $16.1 million $0.05 per unit cash distribution for Q1 2025; $0.20 per unit annualizedSales and purchases YTD 2025:$34.7 million gross sale proceeds from sale of three vessels; average age of 19.1 years Four newbuilding vessels delivered$  3.4 billion contracted revenue as of April 2025PIRAEUS, Greece, May 07, 2025 (GLOBE NEWSWIRE) — Navios Maritime Partners L.P. (“Navios Partners”) (NYSE: NMM), an international owner and operator of dry cargo and tanker vessels, today reported its financial results...

MALVERN, Pa., May 07, 2025 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended March 29, 2025. Highlights1Q 2025 revenues of $715.2 million Gross margin was 19.0% and included the negative impact of approximately 200 basis points related to the addition of Newport 1Q 2025 loss per share of ($0.03) 1Q 2025 book-to-bill of 1.08 with book-to-bill of 1.12 for semiconductors and 1.04 for passive components Backlog at quarter end was 4.7 months“Market signals, which continued from the fourth quarter, indicate that much of the channel inventory that overhung the market has normalized. We executed well during the first quarter on our strategic levers to drive...

First quarter revenue of $753 million, up 7.0%, and up 7.9% on an organic constant currency (OCC) basis. Net income of $232 million, up 5.9%. Adjusted EBITDA, a non-GAAP measure, of $417 million, up 9.5%, and up 9.5% on an OCC basis. Diluted GAAP earnings per share of $1.65, up 8.6%. Diluted adjusted EPS, a non-GAAP measure, of $1.73, up 6.1%.JERSEY CITY, N.J., May 07, 2025 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, today announced results for the first quarter ended March 31, 2025. The earnings release is available on the company’s Investor Relations website at investor.verisk.com. Lee Shavel, President and CEO, Verisk:“I am pleased to share that 2025 is off to a solid start at Verisk as we delivered broad-based top line growth across underwriting and claims and healthy...

KING OF PRUSSIA, Pa., May 07, 2025 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2025. “Vertex continued to perform well in the first quarter, setting us up for a strong 2025,” said David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “Our financial results were in line with our expectations for the quarter, and we made solid progress on key strategic initiatives including e-invoicing and artificial intelligence. We remain very optimistic for our financial outlook for 2025 and our long-term market opportunity in the indirect tax automation space, despite recent geopolitical and market events.” DeStefano added, “Our investment in Kintsugi...

SPOKANE, Wash., May 07, 2025 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for the first quarter of 2025. Net income and earnings per diluted share for the first quarter of 2025 compared to the first quarter of 2024 are presented in the table below (dollars in millions, except per-share data):    2025     2024  Net Income (Loss) by:            Reportable Segments            Avista Utilities   $ 78     $ 67  AEL&P     4       4  Other non-reportable segment loss     (3 )     —  Total net income   $ 79     $ 71  Earnings (Loss) per Diluted Share:            Reportable Segments            Avista Utilities   $ 0.97     $ 0.86  AEL&P     0.04       0.05  Other non-reportable segment loss     (0.03 )     —  Total earnings per diluted share   $ 0.98     $ 0.91  “Strong...

CALGARY, Alberta, May 07, 2025 (GLOBE NEWSWIRE) — TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) today reported its financial results for the first quarter ended March 31, 2025. “Our business delivered strong operational performance across the fleet during the first quarter. While the Company’s merchant portfolio in Alberta was partially impacted by softer power prices, our hedging strategy and active asset optimization continued to generate realized prices well above spot prices,” said John Kousinioris, President and Chief Executive Officer of TransAlta. “We have a unique and diversified generating fleet that is complemented by a highly skilled energy marketing and trading team. Though we are operating within a challenging pricing environment in Alberta, our assets continue to perform...